Development of an innovative, effective, and safe inhalation drug for the treatment of mucus plugs in cystic fibrosis and COPD

Purpose and goal

MucoLife Therapeutics develops a groundbreaking inhaled therapy that effectively dissolves mucus plugs in patients with cystic fibrosis and chronic obstructive pulmonary disease (COPD). The project´s goal is to strengthen the company´s application for the EU´s EIC Transition Grant by developing regulatory, preclinical, and clinical strategies, and establishing clinical partnerships.

Expected effects and result

The project aims to produce a competitive application for the EIC Transition Grant and prepare the company’s groundbreaking inhaled therapy for clinical trials. Results will enhance the company´s capacity to develop modern therapies improving life quality for chronic lung disease patients, boosting Sweden’s international life science competitiveness.

Planned approach and implementation

The project is divided into work packages focusing on regulatory, preclinical, and clinical strategies. Activities include gap analyses, expert strategic meetings, study design development, and collaborations with clinical researchers and consultants, resulting in a robust, compliant, and competitive EIC application.